Spots Global Cancer Trial Database for A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
Official Title: A Phase Ia/Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Runimotamab Administered Intravenously as a Single Agent and in Combination With Trastuzumab in Patients With Locally Advanced or Metastatic HER2-Expressing Cancers
Study ID: NCT03448042
Conditions
Study Description
Brief Summary: This study will evaluate the safety, tolerability, and pharmacokinetics of Runimotamab administered intravenously as a single agent and in combination with Trastuzumab in participants with locally advanced or metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-expressing cancers.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Yale University, New Haven, Connecticut, United States
Washington University; Wash Uni. Sch. Of Med, Saint Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
SCRI Oncology Partners, Nashville, Tennessee, United States
MD Anderson Cancer Center, Houston, Texas, United States
Peter MacCallum Cancer Centre; Medical Oncology, Melbourne, Victoria, Australia
Grand Hopital de Charleroi asbl, Charleroi, , Belgium
Princess Margaret Hospital; Department of Med Oncology, Toronto, Ontario, Canada
Rigshospitalet, København Ø, , Denmark
EDOG - Institut Bergonie - PPDS, Bordeaux, , France
Centre Léon Bérard, Lyon, , France
Institut Claudius Regaud; Pharmacie, Toulouse, , France
Institut Gustave Roussy, Villejuif, , France
Istituto Europeo Di Oncologia, Milano, Lombardia, Italy
ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda Ca' Granda, Milano, Lombardia, Italy
Istituto Clinico Humanitas, Rozzano (MI), Lombardia, Italy
National Cancer Center East, Chiba, , Japan
Seoul National University Hospital, Seoul, , Korea, Republic of
Asan Medical Center, Seoul, , Korea, Republic of
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, , Netherlands
Erasmus MC; Afdeling Kindergeneeskunde, Rotterdam, , Netherlands
National Cancer Centre, Singapore, , Singapore
Hospital Universitario Quironsalud Madrid; Servicio de Farmacia, Pozuelo de Alarcón, Madrid, Spain
Hospital Universitari Vall d'Hebron, Barcelona, , Spain
Fundacion Jimenez Diaz; Servicio de Farmacia, Madrid, , Spain
Centro Integral Oncológico Clara Campal Ensayos Clínicos START, Madrid, , Spain
Hospital Clinico Universitario de Valencia, Valencia, , Spain
China Medical University Hospital, Taichung, , Taiwan
National Taiwan University Hospital, Taipei, , Taiwan
Churchill Hospital, Oxford, , United Kingdom
Royal Marsden Hospital - Surrey, Surrey, , United Kingdom
Contact Details
Name: Clinical Trials
Affiliation: Genentech, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
